Maria Di Bartolomeo

4PUBLICATIONS
23CO-AUTHORS
Molecular targetsOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Feb 08, 2023
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.

Lorenzo Castagnoli, Simona Corso, Alma Franceschini

|Nov 22, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.

Filippo Pietrantonio, Paolo Manca, Sara Erika Bellomo

|Mar 30, 2019
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Maria Di Bartolomeo, Monica Niger, Federica Morano

|Mar 28, 2018
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino

Pageof 1

Frequent Collaborators

2 joint publications

Filippo Pietrantonio

2 joint publications

Sara Erika Bellomo

2 joint publications

Simona Corso

2 joint publications

Alessandra Raimondi